All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Not reported | 2008-004860-37 | A phase IIIb/IV, single-center, randomized, controlled, observer-blind study to assess the effects of topical formulations containing clindamycin-benzoyl peroxide on epidermal functions in subjects wi... | 2008-12-05 | due-trials |
Completed, but no date, and reported results | 2019-003354-92 | A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Adolescents and Adults with Scalp and Body Psoriasis | bad-data | |
Not reported | 2021-006884-67 | A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis Badanie fazy 3, 4-tygo... | 2022-09-29 | due-trials |
Completed, report not yet due | 2021-006885-19 | A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis Badanie przedłużone, fazy 3, wieloośrodk... | 2024-05-28 | not-yet-due |
Reported results | 2021-006902-61 | A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis Badanie fazy 3, 4-tygo... | 2022-09-30 | due-trials |
Not reported | 2021-006903-14 | A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis Badanie fazy 3, 4-tygo... | 2023-06-01 | due-trials |